Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight

The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.

11/10/2026, 1:00 PM • GlobeNewswire

Type 2 Diabetes Clinical Trial and Competitive Landscape Analysis: 200+ Key Companies Shaping the Future of Type 2 Diabetes Therapeutics Space | DelveInsight

DelveInsight released a comprehensive report on the Type 2 Diabetes competitive landscape, analyzing 200+ pipeline drugs from 170+ active players. The report highlights recent approvals including Eli Lilly's FOUNDAYO (orforglipron) and Novo Nordisk's once-weekly insulin options, alongside promising pipeline therapies targeting various mechanisms of action. Key developments include positive Phase III results for CagriSema, elecoglipron, and other novel GLP-1 receptor agonists, with approximately 60+ drugs in late-stage development.

11/10/2026, 1:00 PM • GlobeNewswire

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

11/10/2026, 11:00 AM • GlobeNewswire

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation

The article recommends five biotech stocks as attractive long-term investments: Vertex Pharmaceuticals for its cystic fibrosis dominance and kidney disease pipeline; Amgen for its diversified portfolio with 17 products showing double-digit growth; Gilead Sciences for its strong HIV drug portfolio and expanding oncology presence; Exelixis for its successful oncology focus with Cabometyx; and Regeneron Pharmaceuticals for its recovery driven by new Eylea formulation and Dupixent growth.

11/08/2026, 4:32 PM • The Motley Fool

Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors

The iShares U.S. Pharmaceuticals ETF (IHE) offers lower costs, higher dividend yield (1.4% vs 0.2%), and better 5-year returns (79% vs 38%) compared to the iShares Biotechnology ETF (IBB). IHE focuses on 53 established drugmakers with lower volatility, while IBB provides broader exposure to 243 biotech firms with higher risk. IHE may be preferable for income-focused investors, though IBB suits those seeking broader biotech sector exposure.

11/07/2026, 11:15 AM • The Motley Fool

Amgen Just Gave Its Shareholders Great News

Amgen's cancer drug Imdelltra demonstrated significant efficacy when combined with AstraZeneca's Imfinzi, reducing death risk by 58% in advanced lung cancer patients and extending median survival to 21.1 months versus 12.7 months with Imfinzi alone. With Imdelltra already generating 115% growth and a robust pipeline of 22 double-digit growth products, Amgen's stock may have further upside potential despite its 40% year-to-date gain.

11/02/2026, 12:25 PM • The Motley Fool

Looking For Growth, Income, and Stability? This Stock Could Offer All 3

Amgen is presented as a well-rounded investment option combining growth, income, and stability. The biotech giant posted 10% year-over-year revenue growth to $10.1 billion in Q2, with 22 products delivering double-digit sales growth. Despite upcoming patent cliffs for older drugs like Otezla and Enbrel, newer therapies like Tezspire, Tepezza, and Imdelltra are driving growth. The company demonstrated resilience during market downturns and maintains a strong dividend program with 152% growth over the past decade and a 2.3% forward yield.

10/31/2026, 1:08 PM • The Motley Fool

Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight

The obstructive sleep apnea (OSA) therapeutic landscape is rapidly expanding with 18+ companies developing 22+ pipeline drugs across multiple mechanisms of action. Eli Lilly's ZEPBOUND (tirzepatide) became the first FDA-approved pharmacological treatment for OSA in December 2024. Other major players including Apnimed, Amgen, Mosanna Therapeutics, and Incannex Healthcare are advancing late-stage candidates targeting weight loss, neuromuscular function, and airway control through diverse delivery methods.

10/29/2026, 1:00 PM • GlobeNewswire

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

10/28/2026, 1:00 PM • GlobeNewswire

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue

Amgen and Vertex Pharmaceuticals present contrasting investment profiles: Amgen generates significantly larger quarterly revenues ($8.1B-$10.1B) with moderate fluctuations and expects ~3% growth in 2026, while Vertex shows steady, gradual revenue growth ($2.8B-$3.3B) driven by its cystic fibrosis focus and the promising Alyftrek treatment. Vertex's expansion into autoimmune diseases with Povetacicept could reach $4-7B in peak annual sales, while Amgen's scale and six $1B+ drug franchises provide acquisition capacity despite slower growth.

10/27/2026, 3:25 PM • The Motley Fool

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

The article compares Amgen and Novo Nordisk as investment options for 2026. Amgen shows stronger revenue growth (9.9%) with a diversified portfolio across oncology and rare diseases, while Novo Nordisk boasts higher profitability (33.1% net margin) but faces pricing pressures and competition in the GLP-1 market. The author recommends Amgen for 2026 due to its consistent revenue growth and scale advantages, despite Novo Nordisk's cheaper valuation multiples.

10/27/2026, 10:50 AM • The Motley Fool

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE?

VanEck Biotech ETF (BBH) offers lower costs (0.35% expense ratio) and concentrated exposure to 25 large-cap biotech leaders, outperforming Invesco Biotechnology & Genome ETF (PBE) over the past year. However, PBE delivers higher dividend income (1.3% yield) and slightly better five-year returns through a multifactor selection strategy. BBH is ideal for cost-conscious momentum investors, while PBE suits those seeking income and a diversified factor-driven approach.

10/27/2026, 10:43 AM • The Motley Fool

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy?

RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and IBB (iShares Biotechnology ETF) offer different approaches to healthcare investing. RSPH provides broader, equal-weighted healthcare exposure with lower volatility, higher dividend yield (0.6%), and a lower expense ratio (0.4%), making it suitable for risk-averse investors. IBB offers concentrated biotech exposure with stronger recent returns (35.5% vs 31.9%) but higher volatility and drawdown risk. The choice depends on investor risk tolerance and conviction in biotechnology's momentum.

10/26/2026, 9:53 AM • The Motley Fool

Breakfast News: Science Strikes Back at Cancer

Cancer treatment breakthroughs dominate ESMO 2026 conference with multiple drugs showing significant survival gains. U.S. stocks declined amid AI spending concerns and rising oil prices, with the Fed expected to hold rates steady Wednesday. Several Motley Fool-recommended companies report earnings this week including Alphabet, Amazon, and Mastercard. TransDigm's stock decline reflects valuation compression rather than business deterioration.

10/26/2026, 7:30 AM • The Motley Fool

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH), which concentrates on 25 biotech companies with higher volatility, and Invesco S&P 500 Equal Weight Health Care ETF (RSPH), which diversifies across 61 healthcare companies. While BBH showed stronger 1-year returns (38.3% vs 25.7%), RSPH is recommended for long-term investors due to lower concentration risk, broader diversification, and higher dividend yield, despite slightly higher expense ratios.

10/25/2026, 5:20 AM • The Motley Fool